8F8.F SYNACT PHARMA AB

Healthcare Biotechnology Frankfurt Exchange
1.35 EUR
Close of Nov 11, 2026
0.9680 2.24
Market cap
EUR 75.7M
P/E
-
P/B
5.92x
ROE
-74.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 8F8.F undervalued?

Graham number

The Graham number of SYNACT PHARMA AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SYNACT PHARMA AB fundamental analysis

No fundamental analysis for SYNACT PHARMA AB yet.

SYNACT PHARMA AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SYNACT PHARMA AB

SynAct Pharma AB (publ), a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advance…

Full company profile